Health sciences company PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) late Wednesday announced its entry into a letter of intent with Penta 5 Packaging Inc. and Penta 5 USA, LLC (together the “Penta 5 Group”) through which PreveCeutical intends to acquire the Penta 5 Group and its assets, including over 120 market-ready products … Continue reading “CannabisNewsBreaks – PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Enters LOI to Acquire Penta 5 Group, Extensive Portfolio of Market-Ready Products”
PreveCeutical Medical Inc. enters into a joint venture agreement with Asterion Cannabis Inc. to develop several nature-based cannabinoid products; the products will help the company respond to the demands for personalized and effective cannabis therapies The development agreement will see Asterion inject funds at cost, while PreveCeutical will contribute by way of opening its research … Continue reading “PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Partners with Asterion Cannabis to Develop Organic Cannabinoid Products”
Health sciences company PreveCeutical Medical (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) this morning announced its entry into an agreement to form a joint venture focused on the development of a range of medicinal cannabinoid products, including sublingual tablets, transdermal patches and other jointly evaluated products aimed at treating various ailments such as chronic pain, inflammation, … Continue reading “CannabisNewsBreaks – PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Announces Joint Venture Agreement with Asterion Cannabis Inc.”
Sol-gel nose-to-brain system offers superior drug delivery New extraction protocol makes accurate and precise quantification of cannabinoids possible Establishment of cannabis division to commercialize research developments A recent release from PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) shows that, in cannabinoid extraction technology, the health sciences company is getting it right. The company … Continue reading “PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) “Gets It Right” in Cannabinoid Extraction”
Health sciences company PreveCeutical Medical (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) aims to give its investors more bang for their buck when it comes to research and development (“R&D”), as it has been proven that smaller companies achieve higher R&D productivity. A recent article discussing the company reads: “PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) … Continue reading “CannabisNewsBreaks – PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Strategically Employs R&D Strategy to Achieve Increased Productivity”
Cannabinoid molecule extraction, quantification mark early successes in PreveCeutical’s drug delivery development process PreveCeutical optimistic about prototypical spray applicators in development for cannabinoid therapies Clinical trials of cannabis-based therapeutics anticipated next year PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) is celebrating the achievement of several key milestones in the development of the company’s … Continue reading “PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Building on Key Milestones in Sol-gel Cannabinoid Development”
Health sciences company PreveCeutical Medical (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) is steadfast in its mission of developing preventive therapies for health-conscious consumers who want nature-based products. A recent article discussing the company reads, “In recent months, the company has advanced the testing of its Nature Identical™ peptides toward the treatment and prevention of cancers … Continue reading “CannabisNewsBreaks – PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Advances Nature Identical Peptides Testing”
Smaller companies achieve higher R&D productivity Collaboration with academia key to R&D success Diverse projects increase chance of success Big Pharma is losing the game in drug development. A decade ago, McKinsey & Company sounded the alarm, warning that the biopharma industry was afflicted by “diminishing R&D productivity.” Despite a doubling of investment in research … Continue reading “PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Deploys Winning R&D Strategy”
Health sciences company PreveCeutical Medical (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) today announced that it has successfully optimized its extraction protocol during its soluble gel (“Sol-gel”) drug delivery research and development program. The company augmented the circumstances for extracting cannabinoids from one of its cannabis strains and established a proprietary method for the accurate quantification … Continue reading “CannabisNewsBreaks – PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Develops Proprietary Cannabinoid Extraction Protocol”
Health sciences company PreveCeutical Medical (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) holds a wide array of advanced therapeutic products in its development pipeline, including its Sol-gel delivery platform. The Sol-gel nose-to-brain drug delivery platform delivers a therapeutic compound to a targeted site at a deliberate, controlled rate. A recent article further discussing the company reads: … Continue reading “CannabisNewsBreaks – PreveCeutical Medical Inc.’s (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Developmental Pipeline Houses Comprehensive Range of Advanced Therapeutic Products”